{
  "nctrialId": "HC-1574",
  "title": "A  Double-Blind, Placebo-Controlled Multi-Center Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Cystic Fibrosis",
  "officialTitle": "A  Double-Blind, Placebo-Controlled Multi-Center Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Cystic Fibrosis",
  "sponsor": "McGill University Health Center",
  "indication": "Cystic Fibrosis",
  "phase": "Phase 2",
  "fileName": "HC-1574.json",
  "fileSize": 586266,
  "date": "2024-05-17",
  "completionDate": "2026-06-27",
  "drugName": "PSO-602 (phosphodiesterase-4 inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a  double-blind, placebo-controlled multi-center study designed to evaluate the efficacy and safety of PSO-602 (phosphodiesterase-4 inhibitor) in patients with Cystic Fibrosis. The study will enroll approximately 389 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 26-74 years\n- Confirmed diagnosis of Cystic Fibrosis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}